Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US7034009B2 · kind B2 · utility
32Cited by
10References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 3, 2002 |
| Grant date | Apr 25, 2006 |
| Priority date | — |
| Expiry date | Mar 16, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.